Santhera Pharmaceutical

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases. The company's lead product, Agamree (vamorolone), is a first-in-class dissociative steroid approved in the United States and Europe for the treatment of Duchenne muscular dystrophy (DMD). Agamree is designed to maintain the efficacy of standard corticosteroids while potentially reducing systemic side effects such as bone fragility and growth retardation. Santhera's pipeline also includes lonodelestat, a potent neutrophil elastase inhibitor in Phase 2 development for cystic fibrosis and other inflammatory diseases. The company operates through a combination of direct commercialization in key European markets and strategic partnerships, such as its collaboration with Catalyst Pharmaceuticals in North America.